Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients-authors' reply.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients-authors' reply.
Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients-authors' reply. Aliment Pharmacol Ther. 2017 11; 46(9):905-906.
View in:
PubMed
subject areas
Antibodies, Monoclonal
Biosimilar Pharmaceuticals
Humans
Inflammatory Bowel Diseases
Infliximab